Effects of concomitant use of doxifluridine, radiotherapy and immunotherapy in patients with advanced cervical cancer.

Abstract

Clinical effects of doxifluridine (group A, 600 mg/body/day; group B, 800 mg/body/day) combined with radiotherapy and immunotherapy were evaluated in patients with advanced cancer of the uterine cervix. Response rates were 84.2% (16/19 patients) in group A and 100% (18/18 patients) in group B, respectively (p=0.230). There was no significant difference in adverse reaction incidence between the methods but significantly higher grade adverse reaction were observed in group B than in group A (p=0.048). Time to progression (TTP) was longer in group B than in group A (p=0.081). The optimal 5'-DFUR dose was 800 mg/body (group B), by which higher grade adverse reactions were fully controlled and TTP was prolonged.

• Authors: K Yamamoto, K Noda, M Hatae, T Kudo, K Hasegawa, R Nishimura, H Honjo, A Yajima, S Sato, K Mizutani, M Yakushiji, Y Terashima, K Ochiai, H Sasaki, M Ozaki
• Journal: Oncology reports (Oncol Rep) 2001 Mar-Apr Vol. 8 Issue 2 Pg. 273-7 ISSN: 1021-335X [Print] Greece
• PMID: 11182039 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Multicenter Study)

Chemical References

• Antineoplastic Agents
• Floxuridine
• Sizofiran
• doxifluridine

Topics

• Adult
• Aged
• Antineoplastic Agents (adverse effects, therapeutic use)
• Combined Modality Therapy
• Confidence Intervals
• Disease Progression
• Disease-Free Survival
• Female
• Floxuridine (adverse effects, therapeutic use)
• Humans
• Middle Aged
• Neoplasm Staging
• Sizofiran (adverse effects, therapeutic use)
• Survival Rate
• Time Factors
• Uterine Cervical Neoplasms (immunology, mortality, pathology, radiotherapy, therapy)